Beam Therapeutics: Expected To Boost Pipeline Development Into 2023

Dec. 09, 2022 5:05 PM ETBeam Therapeutics Inc. (BEAM)CRSP, EDIT, VERV1 Comment
Stella Mwende profile picture
Stella Mwende


  • Beam Therapeutics announced the recruitment of its first BEACON trial patient in the middle of November 2022.
  • BEAM's announcement was followed by Editas Medicine's declaration of positive safety and efficacy data from its first two patients enrolled and treated under the Ruby trial.
  • The FDA is also advancing its understanding of the application of base editing which will further contribute to the improvement of in vivo base editing.

Treatment and Adjustment of DNA


Beam Therapeutics (NASDAQ:BEAM) reported Q3 2022 EPS of -$1.56 missing analysts' estimates by $0.47. It fell against revenue of $15.80 million representing a rise of 1,970% (YoY) with a cash balance of $1.09 billion. Beam shares are down 45.61% (YTD) and 49.31% below the 52-week high of $88.18. BEAM uses base editing

Increase in cash used in operating and investing activities in Beam Therapeutics

Seeking Alpha

This article was written by

Stella Mwende profile picture
I have more than five years experience in the financial industry. I focus mostly in the commodities, foreign exchange and cryptocurrencies. I also write on general issues like equity research, economics and geopolitics.Fellow contributor Crispus Nyaga is my colleague.

Disclosure: I/we have a beneficial long position in the shares of BEAM either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.